BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 22, 2020
Finance

HepaRegeniX aims to bring liver program into clinic with €11M insider round

With €11 million ($12.2 million) in fresh series B funding from insiders, liver regeneration company HepaRegeniX hopes to have a first-in-class molecule in the clinic by fall 2020. Participating in the round were Boehringer Ingelheim...
BC Extra | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

Intra-Cellular raises $295M  In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the sale of 10 million shares at $29.50. The price is a 4% discount to Intra-Cellular’s close at...
BioCentury | Dec 4, 2019
Finance

Series B boost for ImCheck's gamma delta T cell therapies

With $53 million in series B funding, ImCheck plans to bring at least one of its T cell-activating antibodies into the clinic and broaden its immuno-oncology pipeline. Pfizer Ventures and two Bpifrance funds, InnoBio 2...
BC Innovations | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors. Boehringer...
BC Extra | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

Beam seeking NASDAQ IPO   Beam Therapeutics filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays and Wedbush PacGrow. The base editing company has 12 preclinical programs across...
BioCentury | Sep 27, 2019
Finance

Via Munich office, Kurma launches oncology company Tacalyx

Tacalyx, the first company created from French VC Kurma’s new Munich office, signals continued interest in tumor-associated carbohydrate antigens (TACAs), the targeting of sugars up-regulated in cancers. Kurma Partners opened the German office early this...
BC Extra | Aug 21, 2019
Company News

Interest in carbohydrate antigens grows with Siamab acquisition

Siamab's acquisition by an undisclosed pharma is the latest example of pharma's growing interest in targeting sugar groups to treat cancer. The announcement comes less than two years after the biotech teamed up with Boehringer...
BC Innovations | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BC Extra | Jul 15, 2019
Company News

July 15 Company Quick Takes: Boehringer takes out cancer vaccine company Amal; plus Farxiga setback, Alkermes and more

Boehringer buying cancer vaccine play Amal  Boehringer Ingelheim (Ingelheim, Germany) is acquiring Amal Therapeutics S.A. (Geneva, Switzerland), a University of Geneva spinout developing cancer vaccines. Amal's shareholders will receive an undisclosed upfront payment; the total...
Items per page:
1 - 10 of 95
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 22, 2020
Finance

HepaRegeniX aims to bring liver program into clinic with €11M insider round

With €11 million ($12.2 million) in fresh series B funding from insiders, liver regeneration company HepaRegeniX hopes to have a first-in-class molecule in the clinic by fall 2020. Participating in the round were Boehringer Ingelheim...
BC Extra | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

Intra-Cellular raises $295M  In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the sale of 10 million shares at $29.50. The price is a 4% discount to Intra-Cellular’s close at...
BioCentury | Dec 4, 2019
Finance

Series B boost for ImCheck's gamma delta T cell therapies

With $53 million in series B funding, ImCheck plans to bring at least one of its T cell-activating antibodies into the clinic and broaden its immuno-oncology pipeline. Pfizer Ventures and two Bpifrance funds, InnoBio 2...
BC Innovations | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors. Boehringer...
BC Extra | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

Beam seeking NASDAQ IPO   Beam Therapeutics filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays and Wedbush PacGrow. The base editing company has 12 preclinical programs across...
BioCentury | Sep 27, 2019
Finance

Via Munich office, Kurma launches oncology company Tacalyx

Tacalyx, the first company created from French VC Kurma’s new Munich office, signals continued interest in tumor-associated carbohydrate antigens (TACAs), the targeting of sugars up-regulated in cancers. Kurma Partners opened the German office early this...
BC Extra | Aug 21, 2019
Company News

Interest in carbohydrate antigens grows with Siamab acquisition

Siamab's acquisition by an undisclosed pharma is the latest example of pharma's growing interest in targeting sugar groups to treat cancer. The announcement comes less than two years after the biotech teamed up with Boehringer...
BC Innovations | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BC Extra | Jul 15, 2019
Company News

July 15 Company Quick Takes: Boehringer takes out cancer vaccine company Amal; plus Farxiga setback, Alkermes and more

Boehringer buying cancer vaccine play Amal  Boehringer Ingelheim (Ingelheim, Germany) is acquiring Amal Therapeutics S.A. (Geneva, Switzerland), a University of Geneva spinout developing cancer vaccines. Amal's shareholders will receive an undisclosed upfront payment; the total...
Items per page:
1 - 10 of 95